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ABSTRACT
Over the past decade, patterns of resistance to antimicrobial agents have changed dramatically,
particularly because of the increasing prevalence of methicillin-resistant Staphylococcus aureus (MRSA),
as well as the increasing rate of antimicrobial resistance seen in several species of Gram-negative
bacteria. The unique nature of the intensive care unit (ICU) environment makes it a focus for the
emergence and spread of many antimicrobial-resistant pathogens. The patients in this setting are
commonly exposed to broad-spectrum antimicrobial agents, and opportunities for the cross-transmis-
sion of resistant bacteria from patient to patient abound. Not surprisingly, resistance rates have
increased for most pathogens associated with nosocomial infections among ICU patients, and rates are
almost universally higher among ICU patients than among non-ICU patients. MRSA strains are now
spreading in the community, possibly because of antibiotic pressure outside the hospital, but also
because of transfer from hospital settings. Such strains are worrisome, particularly the strains carrying
the gene for Panton–Valentine leukocidin (PVL), which has been associated with heightened virulence.
Managing infections caused by today’s pathogens requires avoidance of antimicrobial agent overuse
and appropriate selection, dosing and duration of efﬁcacious antimicrobial therapy.
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INTRODUCTION
The emergence of antimicrobial resistance in
many bacterial species has increased the burden
of nosocomial or healthcare-associated infections
[1]. Within the healthcare setting, the unique
nature of the intensive care unit (ICU) environ-
ment makes it a focus for the emergence and
spread of many antimicrobial-resistant patho-
gens. Patients in the ICU are commonly exposed
to broad-spectrum antimicrobial agents, and the
ICU presents ample opportunities for the cross-
transmission of resistant bacteria from patient to
patient. As a result, rates of colonisation and
infection with antimicrobial-resistant pathogens
are almost always higher among patients in the
ICU than in other healthcare settings, either in or
out of the hospital.
The higher rate of resistance in ICU settings is
illustrated by two analyses from the National
Nosocomial Infections Surveillance (NNIS) Sys-
tem of the US CDC. A survey in 1996 of 41 US
hospitals showed high rates of resistant
pathogens, including methicillin-resistant Staphy-
lococcus aureus (MRSA), methicillin-resistant coag-
ulase-negative S. aureus, vancomycin-resistant
enterococci (VRE), ceftazidime-resistant Pseudo-
monas aeruginosa, and Enterobacter species resistant
to third-generation cephalosporins. The preva-
lence of resistant isolates was higher in ICUs than
in non-critical hospital units, and lowest in out-
patient settings [2]. Similarly, NNIS data from
January 1998 to June 2004 documented higher
prevalences of many resistant isolates among
patients in US ICUs than among patients in non-
ICU settings (Fig. 1) [3].
The hospital has not been the sole environment
for the evolution of antimicrobial resistance, as
shown by the steadily accumulating reports of the
emergence of MRSA in the community [4–9]. The
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spread of antimicrobial-resistant pathogens in
both settings over the last several decades poses
an enormous threat to personal and public health.
The purpose of this review is to describe recent
ﬁndings on MRSA and resistant Gram-negative
pathogens, which are typically virulent and asso-
ciated with difﬁcult-to-treat infections. The impli-
cations of the emergence of these resistant strains
for managing patients with bacterial infections
will be discussed.
MRSA
The impact of methicillin resistance in S. aureus is
manifested as reduced livelihoods, lost lives, and
increased healthcare expenditures [10]. To fully
understand the public health impact of MRSA, it
is necessary to appreciate how widely it has
spread and how prevalent it has become. First
described in the early 1960s with a sprinkling of
reports of sporadic infections, MRSA now has
reached endemicity in many hospitals [11–13]. In
the USA, c. 60% of hospital-acquired S. aureus
isolates are now resistant to methicillin (Fig. 1)
[3]. The MRSA infection rate once roughly corre-
lated with hospital size, but now the prevalence of
MRSA in small community hospitals has reached
that found in large medical centres [13]. In
Europe, the prevalence of MRSA is not as high
as that in the USA, but rates above 25% have been
acknowledged in several countries (Fig. 2) [14].
MRSA has been identiﬁed also as a cause of
community-acquired infections. Community-
acquired MRSA isolates can typically be distin-
guished from the typical nosocomial isolates by
the presence of a particular resistance determi-
nant, the staphylococcal cassette chromosome
mec-IV (SCCmec type IV) and speciﬁc clones
(e.g., predominantly USA300 in the USA and
ST80 in Europe) [15,16]. Also, the gene for
Panton–Valentine leukocidin (PVL) toxin, which
has been associated with necrotising pneumonia
and necrotic abscesses, is common in community-
acquired strains [17–19], although PVL-positive
Fig. 1. Rates of resistance among pathogens associated with nosocomial infection in patients in intensive care units in the
USA; data from the National Nosocomial Infections Surveillance System summarised from January 1992 through June 2004
[3]. MRSA, methicillin-resistant Staphylococcus aureus; MR-CNS, methicillin-resistant coagulase-negative staphylococci;
VRE, vancomycin-resistant Enterococcus species; C ⁄O-R P. aerug, ciproﬂoxacin ⁄ oﬂoxacin-resistant Pseudomonas aeruginosa;
L-R, levoﬂoxacin-resistant; I-R, imipenem-resistant; Ceft-R, ceftazidime-resistant; Pip-R, piperacillin-resistant; Cef3-R,
third-generation cephalosporin-resistant; Carb-R, carbapenem-resistant.
Fig. 2. Prevalence of invasive methicillin-resistant Staphy-
lococcus aureus in Europe in 2005 from the European
Antimicrobial Resistance Surveillance Report [99].
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status alone is not a reliable marker of community
origin in MRSA [20]. Community-acquired MRSA
tends to be susceptible to antibiotic classes other
than b-lactams (e.g., tetracyclines, trimethoprim–
sulfamethoxazole).
In the USA, community-acquired MRSA was
ﬁrst documented in the 1990s with the report of
four fatal paediatric cases [21]. Since then,
reports of MRSA infections in the community
have accumulated. These reports also demon-
strate that the prevalence of community-acquired
MRSA varies among geographical regions. In
studies conducted during 2003 and 2004 in urban
centres across the USA, the prevalence of com-
munity-acquired MRSA ranged from 15% – 76%.
[22–25].
Community-acquired MRSA has also surfaced
in European countries, several of which have
had a history of very low incidence of health-
care-associated MRSA, such as Denmark. Infec-
tions caused by MRSA in Denmark had been
rare until the early 2000s; the prevalence of
MRSA among S. aureus bloodstream infections
was below 1% during the previous three
decades [26]. However, in 2004, the proportion
of MRSA in S. aureus bacteraemia exceeded 1%
for a time, and it remained above 1% in 2005.
Furthermore, the reported number of cases of
MRSA infections (all types) increased eight-fold
between 2000 and 2005 to a total of 856 new
cases in 2005. Most of these cases of MRSA were
community-acquired and were attributed to the
ST80 strain [16,27]. In addition, the USA300
strain has migrated to Denmark, with documen-
tation of the ﬁrst case in 2000, and between 2003
and 2005, the annual incidence increased from
two to 28 cases (a 14-fold increase). Salient
characteristics of these MRSA isolates included
SCCmec type IVa and PVL positivity, which has
been associated with increased virulence [16]. In
The Netherlands, PVL-positive MRSA surfaced
in the late 1980s, starting with the ﬁrst report in
1988. By 2002, PVL genes were found in up to
15% of MRSA isolates, most of which contained
SCCmec type IV [28]. In Belgium, a study of 41
MRSA isolates collected between 2002 and 2004
revealed 16 isolates containing SCCmec type IV
and PVL genes, and 15 of these 16 isolates were
community-acquired [29]. In Switzerland, the
ﬁrst case of community-acquired MRSA was
reported in 2002, and by the end of 2004, 58
cases had been identiﬁed [30].
Community-acquired MRSA strains are most
commonly associated with skin and soft-tissue
infections [31] and have been reported among
individuals with a high degree of skin-to-skin
contact (e.g., athletes, persons in correctional
facilities, military recruits) [32–34]. Respiratory
tract infections and bacteraemia can be caused by
community-acquired MRSA, although it does not
occur as commonly in these types of infections as
in skin and soft-tissue infections. For example, of
the 17 cases of community-acquired staphylococ-
cal pneumonia reported to the CDC during the
2003–2004 US inﬂuenza season, 15 were caused by
MRSA [35]. These cases followed documented
inﬂuenza or inﬂuenza-like illness and occurred in
healthy patients without traditional risk-factors
for MRSA infection.
Community-acquired MRSA has migrated into
the healthcare setting, and theseMRSA stains have
emerged as an important and common cause of
healthcare-associated infection [36–40]. In a study
recently conducted by Skiest et al. at Parkland
Hospital, an urban, teaching hospital in Dallas, TX,
USA, the majority (63%) of patients hospitalised
with a community-acquired S. aureus infection
(i.e., identiﬁed within 72 h of admission) had
MRSA, and patients with MRSA commonly pre-
sented with skin and soft-tissue infection (69%)
[41]. Maree et al. documented an increase in the
prevalence of the SCCmec type IV phenotype
among healthcare-associated MRSA clinical iso-
lates from inpatients at the Harbor-UCLAMedical
Center, Los Angeles, CA, USA from 17% in 1999 to
56% in 2003 (p <0.0001) [42]. In a 2004 study of 116
evaluable cases of MRSA bacteraemia among
patients at the Emory Medical Center in Atlanta,
GA, USA, the MRSA USA300 genotype accounted
for 28% of healthcare-associated bloodstream
infections and 20% of nosocomial MRSA blood-
stream infections [39]. At the Houston VAMedical
Center, TX, USA in 2003–2004, an analysis of 37
randomly chosen clinical MRSA isolates revealed
that 24 isolates (65%) were SCCmec type IV, and
most of these SCCmec type IV isolates (22 of 24) had
the USA300 genotype and were positive for the
PVL gene.[40].
Strains of MRSA with SCCmec type IV and PVL
genes have also been documented as a cause of
infections acquired during hospitalisation in Den-
mark (11 cases), Belgium (one case), and The
Netherlands (six cases) [16,28,29]. Taken together,
these ﬁndings underscore the importance of
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community-associated MRSA as an emerging
nosocomial pathogen, which presents new chal-
lenges to infection control programmes [43].
Another trend in the evolution of S. aureus is
decreasing susceptibility to vancomycin, which
has been the drug of choice for treating MRSA
infection for many years [44]. The distribution of
MICs of vancomycin has been shifting towards
higher values in recent years [45]. Vancomycin-
resistant S. aureus (VRSA) strains with MICs
‡32 mg ⁄L and S. aureus strains with intermediate
susceptibility to vancomycin (vancomycin-inter-
mediate S. aureus (VISA)), shown by MICs rang-
ing from 8 to 16 mg ⁄L, have been documented
[46–51]. VISA has been reported not only among
healthcare-associated MRSA, but also, recently,
among community-acquired MRSA [52].
ANTIBIOTIC-RESISTANT GRAM-
NEGATIVE PATHOGENS
The attention that is being focused on antimicro-
bial resistance in hospitals must include the drug-
resistant Gram-negative organisms, which are
found worldwide [53].
P. aeruginosa
P. aeruginosa is a common cause of serious infec-
tions, including ventilator-associated pneumonia
(VAP) [54,55]. Many studies of antimicrobial
resistance in this species conducted among
patients in ICUs illustrate the threat posed by
resistance.
Findings from the NNIS System of the USA
showed a steady increase in antimicrobial resis-
tance in P. aeruginosa isolates from ICUs between
1993 and 2003, with rates in 2003 of 20% to
carbapenems and c. 30% to third-generation
cephalosporins and quinolones (Fig. 3) [56]. A
study by Hanberger et al. [57] illustrates the
emergence of resistant P. aeruginosa also in
Europe. Among 9166 Gram-negative isolates
obtained from 7308 patients in 118 ICUs in
Belgium, France, Portugal, Spain and Sweden
between June 1994 and June 1995 and character-
ised for susceptibility, P. aeruginosa was one of the
most commonly found species (24% of isolates).
The susceptibility of P. aeruginosa and the other
Gram-negative species to different antimicrobial
agents (according to the breakpoints recom-
mended by the CLSI) varied according to
antimicrobial agent and country. Decreased sus-
ceptibility rates in this species for imipenem
ranged from 16% in Belgium to 24% in France,
and for gentamicin, rates ranged from 7% in
Sweden to 46% in France. Antibiotic resistance in
P. aeruginosa was common among patients with
VAP in a Parisian university hospital ICU as
assessed by Trouillet et al. [58]. They isolated
P. aeruginosa from 135 bronchoalveolar lavage
and ⁄ or peripheral blood samples of 393 patients,
and found a piperacillin resistance rate of 25.2%.
An international study reported data on anti-
microbial susceptibility of approximately 9000
P. aeruginosa isolates obtained during 2000–2001
from lower respiratory tract specimens of hospi-
talised patients in the USA, Canada, and Europe
(France, Germany, Italy, and Spain). Susceptibility
to ciproﬂoxacin was as low as 57.3% in France
and 71.2% in Spain, and imipenem susceptibility
rates ranged from 63.1% in Italy to 77.6% in
Canada [59].
Enterobacteriaceae
A European, multinational study by Hanberger
et al. [57] of isolates from patients in ICUs illus-
trates the high prevalence of antimicrobial resis-
tance in species of Enterobacteriaceae [57]. The
most frequent species of Enterobacteriaceae were
Escherichia coli, Enterobacter spp., Klebsiella spp.,
Serratia spp., Proteus spp.,Morganella morganii and
Citrobacter spp.. These species were the most
frequently found isolates (59%), and resistance
rates for the Enterobacter spp. ranged from 26% –
48% for ceftazidime, 26% – 42% for ceftriaxone,
26% – 54% for piperacillin, and 26% – 51% for
piperacillin–tazobactam [57].
Fig. 3. Antimicrobial resistance among Pseudomonas aeru-
ginosa in intensive care unit patients. Reprinted with
permission [56].
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Acinetobacter baumannii
A. baumannii has become a clinically important
pathogen in hospitalised patients. The prevalence
of Acinetobacter as a cause of Gram-negative pneu-
monia in ICU patients in an NNIS study almost
doubled between 1986 and 2003 (4.2%–7.0%), with
noteworthy increases in resistance to carbapenems
(0%–42%) and third-generation cephalosporins
(18%–68%) over the same period [56]. Similarly,
the majority of 419 A. baumannii isolates identiﬁed
in New York metropolitan area hospitals during
1999 were resistant to ciproﬂoxacin (73%), ceftazi-
dime (69%), and carbapenems (>50%), and an alar-
ming 12% were resistant to all agents tested [60].
Resistant strains of A. baumannii have been
found outside of the USA. In the European study
by Hanberger et al. [57], ﬁndings for Acinetobacter
spp in ICU isolates indicated decreased suscepti-
bility to several agents: to ceftriaxone in 64%–
91% of isolates, to piperacillin in 42%–87%, and
to gentamicin in up to 81% [57]. Alvarez-Lerma
et al. [61] reported ﬁndings from a microbiological
characterisation of 3151 infections associated with
mechanical devices, including those linked to
ventilators, urethral probes, and vascular cathe-
ters, in patients admitted to ICUs in Spain during
2003–2005. Although the annual incidence of
A. baumannii isolates did not change (6.5% in
2003, 5.2% in 2004, and 6.1% in 2005), the
proportion of isolates resistant to imipenem dou-
bled by the end of the study, from 28.6% in 2003
to 49.1% in 2004 to 58.3% in 2005.
MOLECULAR BIOLOGY OF
ANTIBIOTIC RESISTANCE
Bacteria have developed a variety of mechanisms
for withstanding antimicrobial agents. Many spe-
cies have intrinsic resistance to one or more
narrow-spectrum agents. Antibiotic resistance
arises via mutation or by transfer of genes from
other bacteria via conjugation, transformation, or
transduction [62].
MRSA, VRSA and VISA
The mechanisms responsible for the activity of
b-lactams, e.g., methicillin against Gram-positive
species such as S. aureus, and the development of
resistance to these agents are well-understood.
Covalent binding of b-lactams to penicillin-bind-
ing proteins (PBPs) completely or partially inhib-
its the transferase activity of the proteins
(transpeptidase and transglycosylase), with
resultant impedance of cell-wall synthesis and
bacterial growth. The main determinant of resis-
tance to b-lactams in S. aureus is PBP2a, which
has only transpeptidase activity and low afﬁnity
for binding b-lactams. PBP2a is encoded by the
mecA gene on the SCCmec element [63–66].
Resistance in VRSA arises from the vancomycin
resistance gene van [49,67]. This gene comprises
six types (A, B, C, D, E, F, and G) and was
originally discovered in vancomycin-resistant
strains of Enterococcus faecium [68]. Later, vanA
and vanB genes were identiﬁed in VRSA strains.
In selected cases, Enterococcus has been estab-
lished as the source of the vanA gene, illustrating
the role that VRE play in the emergence of
antimicrobial resistance in S. aureus [49,69]. How-
ever, vanA ⁄ vanB are not the only means of
conferring vancomycin resistance, since a recent
publication from a study conducted in a tertiary-
care hospital in northern India reported the
emergence of two strains of VRSA with vanco-
mycin MICs of 32 mg ⁄L and 64 mg ⁄L in which
vanA ⁄ vanB genes were not detected [70].
VISA strains overproduce cell-wall components
and sequester vancomycin, thereby limiting its
penetration into the cell [71,72]. The genetic basis
for intermediate resistance to vancomycin in
S. aureus is not well understood. None of the van
genes have been documented in VISA strains [73].
Microarray analysis reported by Cui et al. [74]
revealed 17 genes, including eight novel genes
that conferred altered susceptibility to vancomy-
cin and teicoplanin after their introduction to the
vancomycin-susceptible S. aureus strain N315.
Overexpression of three of these genes, graF,
msrA2 and mgrA, also conferred reduced suscep-
tibility to oxacillin. The products of several of the
genes identiﬁed in this analysis appear to func-
tion in cell-wall synthesis, consistent with the
characterisation of VISA by Smith et al., which
showed thicker cell walls and three- to eight-fold
overproduction of wall precursors [71]. Increased
production of PBPs, particularly PBP2, in VISA
strains has also been documented [75–77].
Gram-negative pathogens
The mechanism by which Gram-negative bacteria
are able to resist b-lactams differs from that of
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Gram-positive bacteria. b-Lactamase production
is a major mechanism of resistance in Gram-
negative bacteria [78]. The b-lactamases that
confer b-lactam resistance include the extended-
spectrum b-lactamases, the inhibitor-resistant
b-lactamases, and the carbapenemases [78].
Unlike Gram-positive bacteria such as S. aur-
eus, in which the b-lactam resistance gene is
encoded on a chromosomal cassette, b-lactam
resistance genes in Gram-negative species have
been localised to plasmids. For example, carba-
penem resistance in Klebsiella is conferred by
plasmids carrying blaKPC. Furthermore, this plas-
mid can also carry genes encoding for extended-
spectrum b-lactamases as well as resistance
determinants for aminoglycosides and ﬂuoro-
quinolones [79–81]. Resistant Enterobacteriaceae
species isolated from ICUs in the USA carry
plasmids containing genes for extended-spectrum
b-lactamases and other resistance factors [82].
Three main molecular characteristics enable
resistant strains of P. aeruginosa to emerge. The
species has a genetic background that includes a
large number of elements conferring resistance, it
readily mutates, and it easily acquires resistance
from genetic material from other bacteria [83].
ANTIMICROBIAL USE AND
DEVELOPMENT OF RESISTANCE
S. aureushas repeatedly shown the ability to evolve
in response to selective pressures in environments
where b-lactam antibiotics are heavily used [66].
Emergence of VRSA and VISA strains appears
also to be linked to high usage of vancomycin.
Sieradzki et al. documented an early case of
VRSA infection in a patient who had received
vancomycin therapy for 6 weeks for a blood-
stream infection [84]. Three isolates, including the
last one obtained before the patient died, had
vancomycin MICs of 8–16 mg ⁄L. Hiramatsu [46]
reported the isolation of an homogeneous strain
of VISA (MIC of 8 mg ⁄L) from an infected
surgical wound in an infant who had received
4 weeks of vancomycin therapy followed by
12 days of combination therapy consisting of
vancomycin plus arbekacin. Other reports of
isolation of VISA followed, including that by
Smith et al., which documented two of the earliest
cases of infections associated with VISA in the
USA [71]. These two patients had a history of
MRSA infections that were treated with extended
courses of vancomycin. Larger studies, including
those by Fridkin et al. [48] and Skiest et al. [41],
identiﬁed recent vancomycin use as an indepen-
dent risk-factor for infection with VISA strains.
Development of resistance by Gram-negative
bacterial species, including P. aeruginosa, in
response to common and ⁄ or repeated antibiotic
use, has been documented. The epidemiology of
piperacillin resistance in P. aeruginosa among
patients with VAP in a Parisian university hos-
pital was assessed by Trouillet et al. [58]. Multi-
variate logistic regression analysis conﬁrmed
previous ﬂuoroquinolone use as a signiﬁcant
independent risk-factor for development of piper-
acillin-resistant P. aeruginosa infection.
The effect of antimicrobial use on the develop-
ment of resistance inGram-negative infectionswas
explored by Neuhauser et al. in a study of >35 000
non-duplicate Gram-negative aerobic isolates
obtained from patients in ICUs across the USA
between 1994 and 2000 [85]. The most commonly
isolated species were P. aeruginosa (23.0%), Ente-
robacter spp. (14.0%),Klebsiella pneumoniae (13.6%),
and E. coli (11.3%). Overall susceptibility to cipro-
ﬂoxacin during the study period decreased from
86% – 76%. Although E. coli remained susceptible
to ciproﬂoxacin, several other Gram-negative
species showed diminished susceptibility to
ciproﬂoxacin, particularly P. aeruginosa. Varying
rates of cross-resistance of ciproﬂoxacin-resistant
strains of P. aeruginosa, Enterobacter spp. and
K. pneumoniae to gentamicin, ceftazidime, imipe-
nem and amikacin were observed. Use of ﬂuoro-
quinolones in the USA (according to data obtained
from the IMS Health Retail and Provider Perspec-
tive Midas database) during the years in which the
study was conducted rose almost in parallel with
the observed increase in the incidence of cipro-
ﬂoxacin-resistant P. aeruginosa.
Finally, multivariate analysis conducted in the
study by Landman et al. [60] showed that the
prevalence of carbapenem- and ceftazidime-resis-
tant A. baumannii was associated with cephalo-
sporin and aztreonam use (p 0.004 and p 0.03,
respectively).
IMPLICATIONS FOR THERAPY
Rapid initiation of appropriate treatment
Empirical treatment for hospitalised patients
must rapidly eradicate infection to provide
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optimal outcomes. To do this, its coverage must
be sufﬁciently broad to provide activity against
the most likely pathogens, including antimicro-
bial-resistant strains if they are suspected, and
must be initiated on a timely basis [86–92]. This
approach is predicted to reduce mortality in
hospitalised patients with serious infections.
Outcomes in critically ill patients with serious
infections are determined by both timing and
choice of antimicrobial therapy (Fig. 4) [86–92].
The latter is dictated by the types of pathogens
isolated, which can differ among countries and
among hospitals. Thus, knowledge of local resis-
tance patterns is of paramount importance. The
most common reason why initial antimicrobial
therapy was inappropriate is that agents were
employed that did not cover resistant strains of
bacteria, including MRSA and Gram-negative
bacilli, acquired during an ICU stay (e.g., P. aeru-
ginosa, Acinetobacter spp.) [86–88,90].
The importance of timely antibiotic use is
described by Davey and Marwick in this issue
[93]. Delay of initiation of appropriate antimicro-
bial therapy has been associated with greater rates
of mortality in patients with VAP and those with
septic shock [88,94].
Baughman and Kerr [95] documented a signi-
ﬁcantly lower mortality rate in patients with VAP
whose treatment resulted in rapid (days 2–5)
clearance of bacteria, as compared to those
without clearance of bacteria (i.e., >100 CFU ⁄mL
of brochoalveolar lavage ﬂuid) (36% vs. 79%,
respectively). This ﬁnding supports a logical
clinical rationale for not delaying the initiation
of appropriate antimicrobial therapy. To reduce
mortality, the causative pathogen must be elim-
inated as soon as possible, before the patient’s
health status becomes irreversible. Furthermore,
as long as the patient continues to receive inap-
propriate antimicrobial therapy, that patient
remains a reservoir for a resistant pathogen or




The association between antimicrobial use (pre-
vious and extended) and emergence of resistant
strains of S. aureus and Gram-negative pathogens
has already been described. Several other risk-
factors linked to the development of antibiotic-
resistant pathogens have been identiﬁed. Factors
associated with multidrug-resistant hospital-ac-
quired pneumonia [96] and with healthcare-asso-
ciated pneumonia [97] are summarised in Table 1.
These risk-factors, if present, should be taken into
consideration when empirical therapy is selected,
recognising that those for community-acquired
MRSA are different than those for healthcare-
acquired MRSA.
De-escalation to avoid antimicrobial overuse
Clinicians must ﬁnd a delicate balance between
utilising antimicrobial agents in a way that
provides the coverage necessary to maximise
clinical beneﬁts and following antibiotic stew-
ardship principles to minimise the risk of
advancing antibiotic resistance. Data from Ibra-
him et al. and from our group suggest that
institutions can avoid the overuse of antimicro-
bial agents for the treatment of VAP with
several simple practices: discontinuation of ther-
apy if the diagnosis of infection is ruled out;
Fig. 4. Mortality associated with inappropriate vs. appro-
priate initial therapy in intensive care unit patients with a
serious infection [86–90,92,100].
Table 1. Risk-factors for resistant pathogens [96]
Multidrug-resistant nosocomial pneumonia
Antimicrobial therapy in the preceding 90 days
Current hospitalisation for ‡5 days
High frequency of antibiotic resistance in the community
or in the speciﬁc hospital unit
Immunosuppression (due to disease or therapy)
Healthcare-associated pneumonia
Hospitalisation for ‡2 days in the preceding 90 days
Residence in a nursing home or extended-care facility
Home infusion therapy (including antibiotics)
Chronic dialysis within 30 days
Home wound care
Family member with multidrug-resistant pathogen
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switching to a narrower-spectrum drug(s) if the
antibiogram suggests that this is appropriate;
and switching to monotherapy (de-escalation)
and ⁄ or shortening the duration of treatment if
supported by evidence from blinded, rando-
mised clinical trials.
The study by Ibrahim et al. [91] evaluated
treatment of VAP according to a protocol based
in part on previous experience that identiﬁed
MRSA and P. aeruginosa as the most frequently
encountered bacterial pathogens in the medical
ICU at Barnes-Jewish Hospital in St Louis, MO,
USA. Blood and either tracheal aspirate or bronc-
hoalveolar lavage cultures were obtained prior to
the start of antimicrobial therapy. The protocol
mandated that these culture results, along with
the clinical course, be used to guide modiﬁcation
of antimicrobial therapy at 24–48 h. Patients
underwent 7 days of treatment; treatment was
extended only for patients with persistent signs
and symptoms of active infection. The use of this
protocol increased the proportion of patients
receiving initial appropriate therapy (94% vs.
48%, p <0.001) and decreased both the duration
of antimicrobial treatment (8.6 vs. 14.8 days,
p <0.001) and the incidence of a second VAP
episode (8% vs. 24%, p 0.03), with no difference
in mortality rates [91].
The use of limited-spectrum antibiotics for VAP
treatment is possible on the basis of local ecology
and patient considerations (medical history and
clinical status). Our group [92] has developed a
protocol for the treatment of VAP (Fig. 5) that
advocates antimicrobial agent selection based on
the presence (or absence) of risk-factors for
infection with a resistant pathogen. When infec-
tion caused by an antibiotic-resistant pathogen is
suspected, one should initially use broad-spec-
trum antimicrobial therapy, and this should be
followed, if feasible, by a switch to culture-
directed, narrower-spectrum therapy—the
de-escalation strategy—to minimise emergence
of resistance.
Evaluation of this protocol was recently
reported [92]. Of the 115 patients with VAP
enrolled in the study, 100 patients (87%)
received empirical antimicrobial therapy that
was appropriate. Treatment was de-escalated
for 48 patients (42%): 24 patients had combina-
tion therapy changed to monotherapy, nine
patients had treatment switched to a narrower-
spectrum antimicrobial agent, and 15 patients
had treatment switched to monotherapy with a
narrower-spectrum agent. Three patients had re-
escalation of therapy because of poor clinical
response. The mortality rate for patients who
underwent treatment de-escalation was 18%,
which was not signiﬁcantly different than that
for patients without treatment change (11%;
p 0.15). Empirical therapy was escalated in 27
patients (23%) because of pathogen resistance to
the initial agents in seven patients, exclusion of
the pathogen in the spectrum of the initial
therapy in four patients, and poor clinical
response in the other 16 patients.
CONCLUSION
The emergence and spread of antimicrobial-resis-
tant pathogens over the past several decades has
posed an enormous threat to personal and public
health. The costs imposed by antimicrobial resis-
tance can be measured in terms of reduced
livelihoods, lost lives and increased healthcare
expenditures [98].
Unfortunately, the prevalence of antibiotic-
resistant pathogens is on the rise, limiting our
treatment choices. Once a cause of infection only
Fig. 5. Guidelines for ventilator-associated pneumonia
management. Reprinted with permission [92].
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in healthcare settings, antibiotic-resistant patho-
gens, especially MRSA, are now recognised as a
common cause of infections acquired in the
community. Care must be exercised when select-
ing an antimicrobial agent(s) for treatment of
infection or suspected infection, employing
broad-spectrum empirical coverage when the
patient is at risk of infection caused by an
antibiotic-resistant pathogen and targeted, nar-
row-spectrum agents for de-escalation once cul-
ture evidence is available or when the local
ecology and patient characteristics suggest this
approach to be appropriate. The evidence base for
VAP tells us that outcomes of patients with
serious infection are related not only to the
selection of appropriate therapy, but also to the
timely initiation of treatment. Excessive and
inappropriate use of antimicrobial agents selects
for resistant strains; therefore, appropriate antibi-
otic stewardship requires not only the limitation
of inappropriate agent usage, but also the appro-
priate selection, dosing and duration of antimi-
crobial therapy to achieve optimal efﬁcacy in
managing infections caused by today’s resistant
pathogens.
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